Cytomegalovirus DNAemia Detected with Real-Time Polymerase Chain Reaction in Hematopoietic Stem Cell Transplant Patients
- 20 August 2013
- journal article
- Published by Springer Nature in Advances in Therapy
- Vol. 30 (8) , 784-791
Abstract
Cytomegalovirus (CMV) infections continue to cause significant morbidity and mortality in hematopoietic stem cell transplant (HSCT) recipients. Successful pre-emptive therapy in transplant patients depends on the availability of reliable diagnostic tests for CMV infections. The purpose of this retrospective study was to evaluate CMV DNA viral load, incidence of CMV disease and CMV seropositivity, risk factors and correlation between CMV DNA positivity and clinical course in HSCT patients. Two hundred and twenty-five patients who underwent peripheral blood stem cell or bone marrow transplantation between June 2003 and April 2010 were included. A real-time polymerase chain reaction (RT-PCR) assay was used for CMV monitoring. Recipient median age was 42.5 years. CMV seropositivity was 95.6%. CMV DNA positivity determined by RT-PCR was 24.9% among the entire patient group. CMV DNA positivity with RT-PCR was found to be significantly higher in allogeneic transplant recipients than autologous transplant recipients (46.7% vs 14.0%; P < 0.0001). Gender, age, conditioning regimen, stem cell source, underlying disease and recipient and donor seropositivity (alone or paired) were not significant risk factors for CMV DNAemia. We did not observe any CMV end-organ disease. CMV DNAemia was significantly higher in allogeneic transplant recipients than in autologous transplant patients. End-organ disease could be prevented with appropriate pre-emptive therapy.Keywords
This publication has 26 references indexed in Scilit:
- Comparación de las técnicas de reacción de polimerasa en cadena en tiempo real y antigenemia para la detección de citomegalovirus en sangre de niños sometidos a trasplantesRevista chilena de infectología, 2011
- Cytomegalovirus in Hematopoietic Stem Cell Transplant RecipientsHematology/Oncology Clinics of North America, 2011
- Differences in Cytomegalovirus Replication Quantified Using Quantitative Polymerase Chain Reaction and Antigenemia After Allogeneic Stem Cell TransplantationTransplantation Proceedings, 2010
- Comparison of Quantitative Cytomegalovirus Real-time PCR in Whole Blood and pp65 Antigenemia Assay: Clinical Utility of CMV Real-time PCR in Hematopoietic Stem Cell Transplant RecipientsJournal of Korean Medical Science, 2009
- Quantification of DNA in Plasma by an Automated Real-Time PCR Assay (Cytomegalovirus PCR Kit) for Surveillance of Active Cytomegalovirus Infection and Guidance of Preemptive Therapy for Allogeneic Hematopoietic Stem Cell Transplant RecipientsJournal of Clinical Microbiology, 2008
- Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategiesTransplantation and Cellular Therapy, 2003
- Monitoring Cytomegalovirus Infection in Adult and Pediatric Bone Marrow Transplant Recipients by a Real-Time PCR Assay Performed with Blood PlasmaJournal of Clinical Microbiology, 2003
- Ganciclovir Prophylaxis To Prevent Cytomegalovirus Disease after Allogeneic Marrow TransplantAnnals of Internal Medicine, 1993
- Early Treatment with Ganciclovir to Prevent Cytomegalovirus Disease after Allogeneic Bone Marrow TransplantationNew England Journal of Medicine, 1991
- Risk Factors for Cytomegalovirus Infection after Human Marrow TransplantationThe Journal of Infectious Diseases, 1986